Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies

• Published in: International journal of pharmaceutics Vol. 570; p. 118683
• Main Authors: Kumar, Vikas, Mintoo, Mubashir J., Mondhe, Dilip M., Bharate, Sandip B., Vishwakarma, Ram A., Bharate, Sonali S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 30.10.2019
• Subjects: Administration, Oral; Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - metabolism; Binary and ternary solid dispersions; Biological Availability; Calorimetry, Differential Scanning - methods; Chemistry, Pharmaceutical - methods; Dissolution; Drug Carriers - chemistry; Drug Evaluation, Preclinical - methods; Hydrophobic and Hydrophilic Interactions; IIIM-290; In vivo anticancer activity; Male; Mice; Mice, Inbred BALB C; Pharmacokinetics; Polyethylene Glycols - chemistry; Polymers - chemistry; Propylene Glycols - chemistry; PVP K-30; Solubility; Solubility - drug effects; Spectroscopy, Fourier Transform Infrared - methods; IIIM-290; LLOQ; Cmax; Solubility; FT-IR; PVP K-30; Binary and ternary solid dispersions; HP-β-CD; p-XRD; Dissolution; Cdk-4; AUC; PVP K-90; PEG; In vivo anticancer activity; DSC; PEG-PPG-PEG; Tmax; SEM; Pharmacokinetics; HPLC; ULOQ; HPMC
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2019.118683

[Display omitted] The objective of this study was to formulate an anticancer preclinical lead, IIIM-290, loaded in solid dispersions to enhance its solubility, dissolution, and oral pharmacokinetics. IIIM-290 is an in-house preclinical anticancer lead prepared by semisynthetic modification of the natural product rohitukine. It is an orally bioavailable Cdk inhibitor showing efficacy in xenograft models of pancreatic, colon and leukemia cancer. It demonstrated in vivo efficacy at a relatively higher dose owing to its poor aqueous solubility (~8.6 µg/mL). Binary and ternary solid dispersions containing PVP K-30, xanthan gum, and PEG-PPG-PEG were selected after solubility screening of various hydrophilic polymers. Several formulations with varying ratios of polymers, alone and in combination, were prepared and investigated for their effects on the solubility enhancement of IIIM-290. The binary solid dispersion VKB-SD75, prepared with PVP K-30 at the ratio of 1:4 w/w, was identified as the optimized composition that displayed 17-fold improvement in the aqueous solubility of IIIM-290. VKB-SD75 was scaled up to a 100-g scale. IIIM-290 and VKB-SD75 were evaluated for DSC, p-XRD, FTIR, 1H NMR, SEM, in vitro dissolution, and oral pharmacokinetics, as well as for in vivo anticancer activity in the Ehrlich solid tumor model. The oral administration of VKB-SD75 in BALB/c mice resulted in a 1.9-fold improvement in plasma exposure. These findings also correlated well when the formulation was administered to mice in the Ehrlich solid tumor model. The newly developed solid dispersion is expected to reduce the dose of IIIM-290 by ~40–50% in preclinical and clinical studies.